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Volume 109  Number 5  2021 Ultrasonic drug delivery for chemoradiation 1473measured by 3D ultrasound imaging. Acute normal-tissue toxicity from 12 Gy to the lower bowel area was assessed using an
intestinal crypt assay in mice culled 3.75 days posttreatment.
Results: A significant delay in tumor growth was observed with conventional chemoradiation therapy and both microbubble
groups (P < .05 compared with the radiation-only group). Transient weight loss was seen in the microbubble groups, which
resolved within 10 days posttreatment. A positive correlation was found between weight loss on day 3 posttreatment and
tumor growth delay (P < .05; R2 Z 0.76). In contrast with conventional chemoradiation therapy, ultrasound-mediated drug
delivery methods did not exacerbate the acute intestinal toxicity using the crypt assay.
Conclusions: Ultrasound and microbubbles offer a promising new approach for improving chemoradiation therapy for
muscle-invasive bladder cancer, maintaining a delay in tumor growth but with reduced acute intestinal toxicity compared with
conventional chemoradiation therapy.  2020 The Author(s). Published by Elsevier Inc. This is an open access article under
the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Bladder cancer is the 10th most common cancer world-
wide, with approximately 550,000 new cases each year.1
Most are urothelial carcinomas, and approximately a
quarter of these are muscle-invasive bladder cancer
(MIBC) in which cancer spreads into the detrusor muscle
of the bladder wall. Radical cystectomy, the removal of
the bladder, has been the standard of care for decades, but
the potentially severe outcome on the patient’s quality of
life2 has made radiation therapy a frequent alternative.
Concurrent chemotherapy and radiation therapy has been
shown to improve patient survival compared with radia-
tion therapy alone3-5 and is now also considered as a
mainstream treatment option. Gemcitabine-based che-
moradiation treatment is widely used, but the toxicity of
gemcitabine results in both severe systemic side effects
and increased effects of radiation in the healthy bladder
tissue surrounding the tumor.6-8 As many MIBC patients
are elderly and unable to tolerate these effects,8
improving the delivery of gemcitabine to the tumor site
would allow a larger number of patients to receive con-
current gemcitabine-based chemoradiation therapy for
MIBC.
Using a combination of microbubbles and ultrasound
has been shown to be effective in improving both the
penetration of drugs into target tissue and in achieving
spatial localization.9 Clinically, microbubbles have been
used widely as contrast agents for ultrasound imaging.
Microbubbles consist of an inert-gas core, typically to 1-10
mm in diameter and stabilized with lipid, polymer, or
proteins. On exposure to ultrasound, the microbubbles
expand and contract in response to the changing pressure.
At low amplitudes, this enhances the echogenicity of the
blood, enabling improved image contrast. At higher am-
plitudes, the microbubble oscillations can lead to increased
permeability of both blood vessel endothelia and individual
cell membranes and hence increased drug deposition in the
exposed tissue.10 This effect has been successfully
exploited by coinjecting microbubbles with a range of
different drugs.11-13 Improving chemotherapeutic druguptake by ultrasound-mediated drug delivery has been
extensively demonstrated in vitro. Lammertink et al
demonstrated that combining ultrasound and microbubbles
could increase intracellular cisplatin and radiosensitivity in
a head and neck cancer cell line.14 A recent in vitro
experiment also showed that ultrasound-mediated drug
delivery could be used to improve cellular gemcitabine
uptake.15 Spatial localization of drug deposition can be
achieved by loading drugs either into or onto the micro-
bubble coating, using either chemical conjugation or
physical methods, according to the drug properties.10
Application of ultrasound then causes local release of the
drug from the microbubbles, followed by enhanced depo-
sition. The ultrasound beam can be tightly focused onto the
target volume, such that the microbubbles only interact
with ultrasound in that volume. The feasibility of
ultrasound-mediated gemcitabine delivery through coad-
ministration has been shown in pancreatic cancer treatment
both preclinically13 and clinically16,17 and for conjugation
of gemcitabine onto microbubbles in murine pancreatic
cancer.18
In this study, we investigated both gemcitabine delivery
approaches in combination with radiation therapy using the
Small Animal Radiation Research Platform (SARRP, from
Xstrahl Ltd). We measured tumor growth delay and both
systemic and acute normal-tissue toxicity in an orthotopic
MIBC model. The results were compared with conventional
gemcitabine-based chemoradiation therapy to determine
whether these approaches could also maintain tumor
growth delay while reducing toxicity.Methods and Materials
All animal work was carried out in accordance with UK
Home Office Guidelines, per the Animal Research:
Reporting of In Vivo Experiments guideline 2.0,19 and
approved by the University of Oxford’s Animal Welfare
and Ethical Review Body under project licenses
P4B738A3B and P8484EDAE. All mice were purchased
from Charles River Laboratories UK Ltd (Bristol, UK).
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The human bladder cancer cell line, RT112, was obtained
from the German Collection of Microorganisms and Cell Cul-
tures GmbH in 2017 and cultured in RPMI-1640 medium
supplemented with 10% (v/v) fetal bovine serum and 1%
penicillin/streptavidin (Gibco, Life Technologies Ltd, Renfrew,






boxy(polyethylene glycol)-2000] (DSPE-PEG(2000)) were
obtained from Avanti Polar Lipids, Inc (Alabaster, AL). Gem-
citabine hydrochloride (50mg, Y0000657), cholesterol (>99%
from egg white, C8667, Chol), and chloroformwere purchased
from Sigma-Aldrich (Dorset, UK). DPPC, DSPE-PEG(2000)
Biotin, DSPC, and cholesterol were dissolved in chloroform
and stored at e20oC before use.
Synthesis of biotinylated gemcitabine
Because gemcitabine is hydrophilic, conjugation of gem-
citabine onto microbubbles required structural modifica-
tion. Chemical modification of gemcitabine is commonly
used to improve the pharmacokinetic parameters, and
several prodrugs have been used in clinical trials.20 Their
design generally focuses on improving the rapid deamina-
tion of the amine group (N-4 position) or overcoming the
drug resistance.21 In our approach, gemcitabine was bio-
tinylated on the 5’ position of the deoxyribose group to
enable its bioconjugation onto microbubbles through
avidin-biotin linkage.18 The biotin group can be cleaved by
tissue or blood esterases, and this converts the biotinylated
gemcitabine to gemcitabine.
Biotinylated gemcitabine was synthesized by sequential
tert-butyloxycarbonyl (BOC) protection of the 3’-hydroxyl
group (48 hours at room temperature in dioxane/water 5:1)
and the cytosine NH (70 hours at 40oC in dioxane) of
gemcitabine, followed by Steglich esterification of the 5’-
hydroxyl group with biotin (24 hours at room temperature
in dichloromethane) and deprotection with trifluoroacetic
acid in dichloromethane.
Microbubble preparation
Microbubbles were prepared by mixing DSPC, DSPE-
PEG(2000), and DSPE-PEG(2000)Biotin at a molar ratio of
82:9:9 (all chemicals dissolved in chloroform). Chemicals
were mixed in a glass vial and dried overnight on a hot
plate at 50oC. The films were then resuspended with
phosphate-buffered saline (PBS) at the lipid concentration
of 20 mg/mL at 100oC. The suspension was sonicated at
room temperature for 120 seconds at 20% amplitude using
a 20 kHz ultrasonic cell disruptor (Probe sonicator, Q125Sonicator, Qsonica, Newtown, CT). A second sonication
was conducted for 30 seconds at 60% amplitude under
perfluorobutane (F2 Chemicals Ltd, Preston, UK), resulting
in the production of microbubbles. The vials were then
placed on ice for 3 minutes. Avidin (CAT# 189725 from
EMD Millipore) was first dissolved in PBS and then mixed
with the microbubbles by gently inverting the vials several
times (final avidin concentration Z 1 mg/mL). The sus-
pension was centrifuged at 280,g for 5 min at 4oC. After
centrifugation, the unbound avidin in the solution was
separated from the floating microbubbles and the micro-
bubbles were replenished with an equal volume of PBS.
The diameters and concentration of microbubbles were
measured by light microscopy and a custom MATLAB
(Mathworks Inc, Natick, MA) script, as described by Sen-
noga et al.22 Microbubbles were then mixed with gemci-
tabine or biotinylated gemcitabine dissolved in PBS.Cell preparation and orthotopic tumor induction
The MIBC model was generated by orthotopically injecting
CD1-nude mice (6-8 weeks old, female) with human
RT112 bladder cancer cells under ultrasound guidance, as
described by Jäger et al.23 Briefly, RT112 cells were pre-
pared in phenol red-free Matrigel (354262, High Concen-
tration [HC] Phenol-Red Free LDEV-Free, Corning Ltd,
Deeside, UK) and PBS 1:2, and 50 mL (concentration Z
1.5x107 cells/mL) was injected into the bladder wall.
At 5 to 7 days after tumor inoculation, the mean tumor
volume was 45.96  1.93 mm3 measured over 43 mice for
the tumor-growth delay experiment (averaged weight per
animal: 25.38  0.30 g). Mice were then grouped by
random selection, and members of each group were sub-
jected to 1 of the following treatments: (1) sham control;
(2) ultrasound and microbubbles only (MB þ US); (3) ra-
diation only (IR); (4) ultrasound, microbubbles, and radi-
ation (MB þ US þ IR); (5) gemcitabine intravenous
injection (10 mg/kg) and radiation (gem þ IR); (6) ultra-
sound with coadministration of gemcitabine (10 mg/kg)
and microbubbles and radiation (gem þ MB þ US þ IR);
or (7) ultrasound with gemcitabine-conjugated micro-
bubbles and radiation (gembioMB þ US þ IR, with 10 mg/
kg gemcitabine and microbubble concentration Z 3x108
bubbles/mL). The ultrasound and radiation exposure pro-
tocols are described below. Tumor volume was measured
using 3D B-mode imaging (40 MHz transmit frequency,
100% power, 22 dB acquisition gain) from a Vevo 3100
Preclinical Imaging System with a MX550D probe (FUJI-
FILM VisualSonics, Toronto, ON) at least twice per week.
Mice were weighed daily for the first 4 days, then 3 times a
week for the remaining experimental period. Mice were
culled when the tumor reached 300 mm3, when they
developed hematuria, or 53 days posttreatment, whichever
occurred earliest.
For the normal-tissue toxicity experiment, 5 to 7 days
after tumor inoculation, mice were grouped by random
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following treatments: (1) sham control; (2) IR; (3) MB þ
US þ IR (microbubble concentration Z 3  108 bubbles/
mL); (4) gem þ IR (10 mg/kg gemcitabine); (5) gem þ
MB þ US þ IR (10 mg/kg gemcitabine and microbubble
concentration Z 3  108 bubbles/mL); (6) gemcitabine-
conjugated microbubbles and radiation (gembioMB þ IR,
with 10 mg/kg gemcitabine and microbubble concentration
Z 3x108 bubbles/mL); or (7) gembioMB þ US þ IR, with
10 mg/kg gemcitabine and microbubble concentration Z
3x108 bubbles/mL. The ultrasound and radiation exposure
protocols are described below. Mice were culled 3.75 days
posttreatment and subjected to the modified crypt assay as
described below. The concentration of the gemcitabine was
verified by a high performance liquid chromatography.
Ultrasound exposure
An image-guided ultrasound treatment system was devel-
oped to locate the bladder tumor and deliver the drug
(Fig. 1). In this system, an 8 MHz imaging transducer
(L11.5v, Verasonics, Kirkland, WA) was used to locate the
bladder tumor and a 1.1 MHz annular focused therapeutic
transducer (H102, bandwidth Z 220 kHz, aperture Z 64
mm, geometric focal distance Z 63.2 mm, Sonic Con-
cepts, Bothell, WA) was used to deliver the therapeutic
ultrasound beam. The beam width (full width at half-
maximum) of this transducer in the lateral and elevation
planes were measured to be 1.2 mm each. The therapeutic
transducer was connected to a radio frequency power
amplifier (1040L, E&I Ltd., Rochester, NY), which was
driven by an arbitrary waveform generator (33220A, Agi-
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Fig. 1. Schematic of the image-guidimaging transducer was placed at right angles to the ther-
apeutic transducer, and both transducers were positioned at
45o to the horizontal to ensure their beams intersected at
the tumor site. The therapeutic transducer was aligned to
the targeted area using a 0.2-mm-diameter needle hydro-
phone (Onda HN0200, Onda Corporation, Sunnyvale, CA).
The imaging transducer was operated by the Vantage sys-
tem (Verasonics, Kirkland, WA). The beam width of the
therapeutic transducer was expanded with a biconvex lens
to enable coverage of the whole bladder. With the expan-
sion lens, the beam width was measured to be 6 mm in
elevation and lateral planes, and the focal distance was
moved to 110 mm. The propagation distance between the
target site and the therapeutic transducer was 110 mm, and
the beam width was 6 mm in elevation and lateral planes.
The position of the therapy transducer was fixed. Before
the start of the experiments, the imaging transducer was
aligned to the focal region of the therapy transducer using a
needle hydrophone (Onda HN0200). The position of the tip
of the needle hydrophone was marked in the ultrasound
image, and the target site was aligned to the same position
using image guidance. The therapeutic ultrasound exposure
parameters were as follows: 1.1 MHz center frequency, 1
MPa peak negative pressure, 1% duty cycle, and 0.5 Hz
pulse repetition frequency. The acoustic settings were
chosen to allow for microbubble reperfusion after micro-
bubble destruction. Microbubble-drug mixtures were
injected via a syringe pump (flow rate for each injection Z
0.5 mL/min, AL-1000, World Precision Instruments) 8
times, using 25 mL of suspension each time, and 40 ther-
apeutic ultrasound pulses were applied between each in-
jection to burst the microbubbles. Two hundred microliters
of suspension were injected to each mouse. The Vantageembrane





ed ultrasound treatment system.
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control the function generator for the therapeutic pulse
delivery as well as the syringe pump for the microbubble
injection to guarantee routine and accurate administration
of both.
Radiation with the Small Animal Radiation
Research Platform
Approximately 6 hours after gemcitabine and/or ultrasound
treatment, mice were irradiated using the SARRP (Xstrahl
Ltd), delivering 220 kV x-rays, 13 mA, half-value layer
0.794 mm Cu. For tumor growth delay experiments, mice
were irradiated vertically as described by Groselj et al24
with temperature maintained homeothermically,25 to a
dose of 6 Gy, using a 356 arc treatment and with a circular
collimator, typically between 5.2 and 8.4 mm, to cover the
whole bladder and minimize any normal-tissue damage.
For the acute normal-tissue toxicity experiments, to cover a
greater volume of bowel, mice were treated supine, and 12
Gy was delivered to the lower abdomen including the small
intestine by the SARRP, using a 178 arc treatment and
with a 14-mm circular collimator.
Modified crypt assay
The “Swiss roll” crypt assay was conducted as described by
Groselj et al.24 The small intestines from the mice were
collected and rolled up to provide “Swiss rolls” for his-
tology. Samples were cut into 5-mm slides and subjected to
hematoxylin and eosin staining. The slides were scanned
using an Aperio CS2 digital pathology slide scanner (Leica
Biosystems, Wetzlar, Germany) and analyzed anonymously
using Aperio ImageScope software (Leica Biosystems).
The percentage of crypts surviving was calculated as
follows:
Number of crypts from irradiated mice
Number of crypts from control mice
 100
Statistical analysis
Statistical analyses were performed with Prism (GraphPad),
and results were presented as mean  SEM. Multiple group
comparisons were made using 1-way ANOVA followed by
a post hoc Tukey multiple comparison test. The Kaplan-
Meier curve was used to present the time to triple tumor
volume. One mouse from the gem þ MB þ US þ IR group
and 1 from the gembioMB þ US þ IR group survived to
the endpoint (53 days posttreatment) without reaching the
3-fold volume increase. Two mice from the gembioMB þ
US þ IR group were censored (culled) owing to hematuria,
1 at day 33 and 1 at day 45, but the tumors had not reached
a 3-fold volume increase. Those times were also included
as the times to triple tumor volume. The log-rank test was
conducted on the Kaplan-Meier curve before day 32 todetermine statistical significance (P < .05). Pearson corre-
lation was used to study the relationship between 2 pa-
rameters with a 2-tailed P value.
Results
Combining ultrasound-mediated drug delivery and
radiation demonstrated improved tumor growth
delay similar to conventional gemcitabine-based
chemoradiation therapy
The tumor size was approximately 30 to 80 mm3 before the
treatment started and showed no difference among different
treatment groups (Fig. E1a). Ten days posttreatment, more
than half of the mice from the control group had reached
the humane endpoint (tumor volume of 350 mm3).
Compared with the controls showing a mean tumor size of
297.3  28.4 mm3, significant tumor growth delay was
found in the following groups: gem þ IR (85.34  16.0
mm3, P < .001), MB þ US þ IR (132.5  41.2.0 mm3, P <
.01), gem þ MB þ US þ IR (144.7  35.8 mm3, P < .01),
and gembioMB þ US þ IR (94.6  25.0 mm3, P < .001)
(Fig. E1b). No difference in tumor volume was found be-
tween the control mice and mice subjected to radiation only
(IR, 176.5  28.3 mm3) or to microbubbles and ultrasound
without drug or irradiation (MB þ US, 218.4  23.5 mm3)
(Fig. E1b). At 14 days posttreatment, compared with those
in the MB þ US only group (mean tumor volume, 328.3 
12.9 mm3), only mice subjected to conventional chemo-
radiation therapy (gem þ IR, 123.9  21.3 mm3) or ul-
trasound with gemcitabine conjugated microbubbles and
irradiation (gembioMB þ US þ IR, 122.3  37.9 mm3)
still showed significant tumor growth delay (Fig. 2a and 2b,
P < .05 for each). Overall, the time to triple tumor volume
for gembioMB þ US þ IR groups (mean Z 25.6  6.8
days; 95% CI Z 8.8-42.3 days) was also significantly
prolonged compared with the control group (mean Z 5.25
 0.6 days; 95% CI Z 3.9-6.6 days) (Fig. 2c; control
versus gembioMB þ US þ IR, P < .05).
The Kaplan-Meier curve for time to triple volume
showed significantly delayed tumor growth in the gem þ
IR and gembioMB þ US þ IR groups compared with the
IR-only group (Fig. 2d, P < .05 for each). However, no
significant difference in the time to triple volume was
detected between the gem þ IR group and all 3 ultrasound-
mediated drug delivery groups (MB þ US þ IR, gem þ
MB þ US þ IR, and gembioMB þ US þ IR) (Fig. 2d).
Whereas most of the mice in the IR-only group had their
tumor volume triple by 10 days posttreatment, the median
time to triple volume for mice subjected to gem þ IR and
gembioMB þ US þ IR was 14 and 18 days, respectively
(P < .05 for each). The median time to triple volume for
MB þ US þ IR was 12 days but was only marginally
different from the IR-only group (P Z .05). Similar to the
IR-only group, the gem þ MB þ US þ IR group also
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Fig. 2. Orthotopic muscle-invasive bladder tumor growth delay observed by combining ultrasound-mediated drug delivery
and radiation. (a) Tumors from mice treated with gem þ IR and gembioMB þ US þ IR were still significantly smaller than
those in mice treated with MB þ US 14 days posttreatment; )P < .05 compared with control. (b) Tumor growth curve until
day 14 posttreatment. (c) Mice treated with gembioMB þ US þ IR had prolonged time to triple tumor volume compared with
the control group; )P < .05 compared with control. (d) Kaplan-Meier survival curve showing plots of time to triple tumor
volume after the treatments; control versus IR: P < .01; IR versus gem þ IR and IR versus gembioMB þ US þ IR: P < .05. n
Z 8 for control; n Z 4 for MB þ US; n Z 6 for IR, gem þ IR, MB þ US þ IR, and gem þ MB þ US þ UR; and n Z 7 for
gembioMB þ US þ IR. Abbreviations: gem Z gemcitabine; gembioMB Z gemcitabine-conjugated microbubbles; IR Z
radiation; MB Z microbubbles; US Z ultrasound.
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radiation demonstrated transient weight loss and
was correlated with tumor growth delayAnimal weight was measured as an indicator of systemic
treatment toxicity. Weight was presented as the percentage
difference in weight before and each day after treatment
(Fig. E2a). Weight loss was observed from all the treatment
groups 1 day after treatment (Fig. 3a). Mice from the gem
þ IR group experienced a weight loss of only 1.8  0.7%
on day 1, but this was not significantly different from the
control. One day after treatment, compared with thecontrol, we found a significant weight loss for the 3
ultrasound-mediated drug delivery groups: MB þ US þ IR
(4.7  1.4%, P < .05), gem þ MB þ US þ IR (5.0 
1.1%, P < .05), and gembioMB þ US þ IR (6.6  1.0%,
P < .001) (Fig. E2b). Significantly different weight loss
(5.2  2.1%) for the gembioMB þ US þ IR group
compared with the control group lasted until day 3
(Fig. 3b; control versus gembioMB þ US þ IR, P < .05).
By day 10, most mice from all groups had recovered their
weight to within 5% of baseline (Fig. 3c). However, we
found a positive correlation, as more weight loss in day 3
was associated with longer time to triple tumor volume
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Fig. 3. Weight change inmice bearing orthotopic muscle-invasive bladder tumor posttreatment. (a) Daily weight change after
treatment for conventional chemoradiation therapy (gem þ IR) and IR with the 3 ultrasound-mediated drug delivery methods
(MB þ US þ IR, gem þ MB þ US þ IR, and gembioMB þ US þ IR). (b) Three days posttreatment, only mice from the
gembioMB þ US þ IR group showed significant weight loss compared with control; )P < .05 compared with control. (c) All
weight loss was resolved 10 days posttreatment. (d) A positive correlation (P<.05; R2Z 0.76) was found betweenweight loss at
day 3 and time to triple volume in the gembioMBþUSþ IR group. nZ 8 for control; nZ 4 forMBþUS; nZ 6 for IR, gemþ
IR, MB þ US þ IR, and gem þMB þ US þ UR; and nZ 7 for gembioMB þ US þ IR. Abbreviations: gemZ gemcitabine;
gembioMB Z gemcitabine-conjugated microbubbles; IR Z radiation; MB Z microbubbles; USZ ultrasound.
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acute normal-tissue toxicity from chemoradiation
therapy
We then evaluated acute normal-tissue toxicity by using the
SARRP to cover a greater volume of bowel. Mice were
irradiated in a supine position, and the beams were posi-
tioned to cover only part of the bladder and to include the
surrounding bowel tissue. We used a 12 Gy radiation dose,
as 6 Gy was insufficient to induce discernible damage in the
intestine. Mice were culled 3.75 days posttreatment, and
their small intestines were collected to make Swiss rolls for
histology. The most damaged areas of the intestine in eachgroup were identified, and the crypts from those areas were
counted. Compared with mice irradiated with 12 Gy, which
had 8.7  1.1% remaining crypts, significant crypt loss was
found in the conventional gem þ IR group and the gem-
bioMB þ IR group, with only 2.3  0.5% and 1.9  0.3%
crypts remaining, respectively (Fig. 4b; 12 Gy versus gem
þ 12 Gy or gembioMB þ 12 Gy, P < .01). The crypt
damage in these groups was similar to the damage caused
by 14 Gy irradiation (Fig. 4a). On the other hand, no sig-
nificant change in crypt survival was found between IR
only and all 3 ultrasound-mediated drug delivery
approaches (Fig. 4b). The MB þ US þ 12 Gy group had






























































Fig. 4. Acute normal tissue toxicity. (a) Representative images of intestinal crypt from each treatment group. Scale bar
represents 100 mm. (b) Assessment of acute normal tissue toxicity using crypt survival. Conventional chemoradiation therapy
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bioMB þ US þ 12 Gy group had 7.0  1.8% remaining
crypts. Significant differences were found between gem þ
IR or gembioMB þ IR and MB þ US þ IR (Fig. 4b; P <
.001 for each). A marginal difference was detected between
gem þ IR and gembioMB þ US þ IR (P Z .06), and a
significant difference was detected between mice treated
with gembioMB þ IR and gembioMB þ US þ IR (Fig. 4b;
P < .05), suggesting that ultrasound is indeed essential in
reducing normal-tissue toxicity.Discussion
In this study, we tested the hypothesis that using micro-
bubbles and ultrasound reduces local toxicity compared with
conventional chemoradiation without compromising treat-
ment efficacy. The conventional chemoradiation was
modeled by intravenous injection of 10 mg/kg gemcitabine 6
hours before irradiation (gem þ IR). Under the same sys-
temically administrated gemcitabine dose and radiation
regimen, we explored 2 different gemcitabine administration
approaches to improve the gemcitabine delivery to our
in vivo model using ultrasound-mediated drug delivery:
coadministration of microbubbles and gemcitabine and
conjugation of gemcitabine onto microbubbles via avidin-
biotin linkage. As described in the introduction, both
methods have been previously shown to be feasible in
treating pancreatic cancer. We showed that both treatments
were associated with tumor growth delay comparable with
that of conventional chemoradiation. Although a transient
systemic toxicity, as indicated by the weight loss, was found
in both groups, there was also reduced acute intestinal-tissue
toxicity from the conventional chemoradiation.
The advantage of combining ultrasound-mediated drug
delivery using coadministration of microbubbles and
gemcitabine with ionizing radiation (gem þ MB þ US þ
IR) was its straightforward implementation in clinical
practice. In our study, this technique initially showed
comparable tumor growth delay compared with the gem þ
IR groups (Fig. E1a), but the effect was only comparable
with that of IR at a later time point (Fig. 2). Weight loss
compared with the control group was significant 1 day after
treatment but not significant after day 2. This method also
reduced the intestinal toxicity compared with the gem þ IR
group (Fig. 4). On the other hand, we showed that
gemcitabine-conjugated microbubbles and ultrasound with
radiation therapy (gembioMB þ US þ IR) is more efficient
in delaying tumor growth. This technique showed tumor(gem þ 12 Gy) or gembioMB þ 12 Gy resulted in significant re
There was no difference between 12 Gy and the 3 ultrasound-me
MB þ US þ 12 Gy, and gembioMB þ US þ 12 Gy), indicatin
chemotherapy could be avoided; )P < .05, ))P < .01, )))P <
Abbreviations: gem Z gemcitabine; gembioMB Z gemcitabine
bubbles; US Z ultrasound.growth delay comparable with the gem þ IR group, even at
later time points (Fig. E1 and Fig. E2). Significant weight
loss from this group was still found on day 3 but not after
day 6 (Fig. 3). This approach showed reduced intestinal
toxicity compared with that observed in the gem þ IR
group (Fig. 4). In addition, this approach improved
crypt survival, compared with administering only
gemcitabine-conjugated microbubbles (Fig. 4). The lack of
ultrasound-mediated destruction of gemcitabine-conjugated
microbubbles may result in exposure of nontumor tissues to
gemcitabine for longer, potentially increasing uptake of the
drug by those normal tissues.
We also tested the direct effects of ultrasound-mediated
drug delivery by applying microbubbles and ultrasound
without gemcitabine. Previous studies showed that this
application could also radiosensitize tumors, potentially
through effects of vascular damage, when the treatment was
delivered simultaneously with or no more than 6 hours
before radiation therapy.26-29 Applying ultrasound-
mediated delivery without radiation did not achieve
improved delay in tumor growth (Fig. 2). We found that
when combined with radiation, this approach could reduce
intestinal tissue toxicity (Fig. 4), achieving a delay in tumor
growth and systemic toxicity similar to that observed using
gem þ MB þ US þ IR (Fig. E1 and Fig. 2).
We showed that combining ultrasound-mediated drug
delivery with radiation (MB þ US þ IR, gem þ MB þ US
þ IR, or gembioMB þ US þ IR), although it resulted in
transient systemic toxicity, was safe. Only transient weight
loss, which resolved at approximately10 days posttreat-
ment, was found during the study (Fig. 3). Previous reports
have shown that ultrasound can cause gut damage, such as
reduction of mitotic cells and petechiae.30,31 It is possible
that the transient weight loss observed in this study was a
result of mechanical damage on the gut by ultrasound, but
this did not significantly enhance the acute intestinal
toxicity when combined with radiation. We also found the
treatment-associated weight loss was positively correlated
with tumor growth delay for the gembioMB þ US þ IR
group, as more weight loss was associated with longer
tumor growth delay. Some studies have shown that ultra-
sound may have immunomodulatory effects.32-34 As CD1-
nude mice still have innate immunity, it is possible the
that treatment may cause cytokine expression from the
local treatment area to the circulation, modulating other
physiological effects and causing weight loss.35 Further
studies are needed to understand whether the local effect of
tumor growth delay and the systemic effect of weight loss
can be attributed to immune response from the treatment.duction in crypt survival compared with IR at 12 Gy only.
diated drug delivery methods (MB þ US þ 12 Gy, gem þ
g that exacerbation of normal-tissue toxicity by addition of
.001. nZ 5 for 12 Gy, and nZ 4 for all of the other groups.
-conjugated microbubbles; IR Z radiation; MB Z micro-
Volume 109  Number 5  2021 Ultrasonic drug delivery for chemoradiation 1481Clinically, normal-tissue toxicity limits the ability to
cure cancers by limiting the dose of chemotherapeutic
agents or radiation that can be delivered. To improve the
efficacy of chemoradiation therapy, the 2 commonly used
approaches are finding alternative radiosensitizers with less
normal-tissue toxicity or using radioprotectors. The former
approach generally requires development of new drugs,
which is time and resource consuming.36 Radioprotectors
are usually administered before radiation exposure. Several
radioprotectors have been developed to reduce acute in-
testinal radiation injury, but most are still in the preclinical
phase of development and have not been tested in combi-
nation with chemoradiation.37 This study provides an
alternative approach by combining ultrasound-mediated
drug delivery with chemoradiation therapy. We showed
the efficacy in an orthotopic model of muscle-invasive
bladder cancer, which is more clinically relevant than the
models used in most chemoradiation preclinical studies,
namely ectopic xenograft tumor models, coupled with
normal-tissue toxicity studies in the relevant organs that
display dose-limiting toxicity. We showed that we were
able to reduce normal-tissue toxicity without compromising
tumor control, using a common and clinically approved
chemoradiation agent, gemcitabine. The technology can be
immediately applied to other clinically available chemo-
radiation agents to improve the efficacy of chemoradiation
therapy.Conclusion
Using microbubbles and ultrasound to deliver chemo-
radiation therapy was found to reduce local normal-tissue
toxicity compared with conventional chemoradiation
without compromising treatment efficacy. Conjugating
gemcitabine onto microbubbles was found to be more
effective than coadministering microbubbles and gemcita-
bine in terms of long-term delay in tumor growth. Ultra-
sound and microbubbles alone were found to produce a
similar delay in tumor growth but with reduced toxicity
compared with coadministered microbubbles and gemci-
tabine. Combing ultrasound-mediated drug delivery with
radiation resulted in transient systemic toxicity, but this
resolved 10 days posttreatment. As ultrasound and micro-
bubbles have been extensively used in the clinic for both
diagnosis and therapeutic purposes, clinical trials to further
assess the safety and efficacy of incorporating ultrasound-
mediated drug delivery into chemoradiation therapy should
be considered.References
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